Industry Roundup: FPLA changes; Nutroganics in soy market; spiked product, supplement-beverage warnings; Kamil chairs CRN
This article was originally published in The Tan Sheet
FPLA changes proposed; Nutroganics invests to reach soy market; Shoreside hits spiked ingredient trifecta; NYSW blurs supplement-beverage line; Kamil elected CRN chair; and more news in brief.
You may also be interested in...
FDA warning letter on Dewmar’s Lean Slow Motion…Potion line is the first addressing differences between products marketed as conventional beverages and as liquid supplements since a final guidance in January. Attorney Justin Prochnow says the warning could signal an FDA crackdown on melatonin in conventional beverages.
Delaware district judge rules against AstraZeneca’s claim the IRA violates its due process rights, echoing findings made by Ohio district judge in Chamber of Commerce’s suit. Only other IRA ruling to date dismissed PhRMA’s complaint on procedural grounds without addressing the merits.
Lumicell’s Cancer Imaging Drug Faces Clinical Meaningfulness, Anaphylaxis Risk Questions At FDA Panel
US FDA advisory committee briefing documents say drug-device combo Lumisight (pegulicianine) is effective at picking up cancer but it is not clear whether that translates to patient benefit.